Drug intelligence / Profile preview

IMAVAC

Development stage: Preclinical
Lead developer: Vactech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

IMAVAC is a virus-like particle (VLP) technology platform developed by Vactech. It is designed to facilitate the development of vaccine candidates by mimicking the structure of viruses without containing infectious genetic material. The platform is currently in the preclinical stage and serves as a foundation for creating various vaccine assets, particularly targeting viral infections. IMAVAC is intended to induce robust immune responses by presenting viral antigens in a highly organized, repetitive manner that resembles a natural virus, thereby enhancing the immune system's recognition and response.

Brand names: IMAVAC
Other names: IMAVAC™

Targets

BCR (Immunoglobulin G B Cell Receptor)T-cell receptor recognizing enterovirus-derived peptides presented by MHCCoxsackievirus B capsid protein

Beyond the preview

Go deeper on IMAVAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMAVAC.

Explore the full profile